Risk Mitigation in Reality: Best Practices from a Transmucosal Fentanyl REMS
Sponsored by Cephalon Ready for REMS
This activity is not certified for credit.
Date
Wednesday, September 7, 2011
Start Time
8:30 am Registration
End Time
9:30 am
Room
Mont-Royal Ballroom
Level 4
Program Description
This symposium reviews the necessity for the FDA-mandated Risk Evaluation and Mitigation Strategies (REMS) and its components. Faculty will also review a model of a Transmucosal Immediate Release Fentanyl (TIRF) REMS system using an approved REMS and will provide practical guidance and resources for implementing REMS into your practice. Time will be allotted for Q&A at the end of the symposium.
Learning Objectives
By the end of the symposium, you will understand:
- The evolution of risk management in pain medicine
- The principle of balance with opioid treatment
- The requirements of a Transmucosal Immediate Release Fentanyl (TIRF) REMS
- How to support the implementation of REMS into your practice
Faculty
Michael J. Brennan, MD
The Pain Center of Fairfield
Fairfield, CT
Web site
www.cephalonrems.com
Contact Name
Lisa Miccinilli
Contact Phone
201-560-5519
- Pathophysiology of Pain: Mechanisms and Manifestations
- Responsible Opioid Prescribing in the Era of REMS
- Risk Mitigation in Reality: Best Practices from a Transmucosal Fentanyl REMS
- Persistent and Breakthrough Cancer Pain
- Chronic Pain: Best Practices in Interdisciplinary Multimodal Management
